FRACTYL HEALTH/$GUTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About FRACTYL HEALTH
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Ticker
$GUTS
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
109
ISIN
US35168W1036
Website
FRACTYL HEALTH Metrics
BasicAdvanced
$80M
-
-$1.84
-
-
Price and volume
Market cap
$80M
52-week high
$4.92
52-week low
$0.87
Average daily volume
692K
Financial strength
Current ratio
2.502
Quick ratio
2.24
Long term debt to equity
885.224
Total debt to equity
963.529
Profitability
EBITDA (TTM)
-95.834
Gross margin (TTM)
48.33%
Net profit margin (TTM)
-148,511.67%
Operating margin (TTM)
-161,246.67%
Management effectiveness
Return on assets (TTM)
-49.05%
Return on equity (TTM)
-196.81%
Valuation
Price to revenue (TTM)
1,321.515
Price to book
12.58
Price to tangible book (TTM)
12.58
Price to free cash flow (TTM)
-0.99
Free cash flow yield (TTM)
-101.00%
Free cash flow per share (TTM)
-165.64%
Growth
Revenue change (TTM)
-59.46%
Earnings per share change (TTM)
-80.04%
3-year earnings per share growth (CAGR)
-60.98%
What the Analysts think about FRACTYL HEALTH
Analyst ratings (Buy, Hold, Sell) for FRACTYL HEALTH stock.
FRACTYL HEALTH Financial Performance
Revenues and expenses
FRACTYL HEALTH Earnings Performance
Company profitability
FRACTYL HEALTH News
AllArticlesVideos
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
GlobeNewsWire·1 week ago
Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
GlobeNewsWire·1 week ago
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for FRACTYL HEALTH stock?
FRACTYL HEALTH (GUTS) has a market cap of $80M as of June 30, 2025.
What is the P/E ratio for FRACTYL HEALTH stock?
The price to earnings (P/E) ratio for FRACTYL HEALTH (GUTS) stock is 0 as of June 30, 2025.
Does FRACTYL HEALTH stock pay dividends?
No, FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next FRACTYL HEALTH dividend payment date?
FRACTYL HEALTH (GUTS) stock does not pay dividends to its shareholders.
What is the beta indicator for FRACTYL HEALTH?
FRACTYL HEALTH (GUTS) does not currently have a Beta indicator.